Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences develops and commercializes medicines for HIV, viral hepatitis, COVID-19 and cancer. Company updates regularly cover product sales and operating results, HIV franchises such as Biktarvy, Yeztugo and lenacapavir, and clinical or regulatory activity for investigational HIV regimens that combine established antiretroviral agents with newer mechanisms.
Recurring developments also include oncology pipeline expansion through Kite cell-therapy programs, the completed acquisition of Arcellx and its investigational BCMA-directed CAR T-cell therapy anitocabtagene autoleucel for multiple myeloma, collaboration activity using real-world evidence in oncology R&D, shareholder matters, and capital-structure disclosures tied to material agreements and acquisitions.
Gilead (NASDAQ:GILD) highlighted collaborative efforts with the South African government, the Global Fund and the U.S. State Department via PEPFAR to launch lenacapavir, a long-acting HIV prevention medicine, in South Africa.
The company emphasizes royalty-free voluntary licenses with six manufacturers, enabling future generic supply across 120 low- and lower-middle-income countries and supporting local manufacturing to strengthen long-term access.
Gilead Sciences (Nasdaq:GILD) and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines, adding clinical-stage T cell engager gamgertamig (OM336) to Gilead’s inflammation portfolio and Lakefront’s pipeline.
Gilead pays $1.675B upfront plus up to $500M milestones. Lakefront gains Ouro’s team and assets, 20%–23% royalties on gamgertamig, three preclinical autoimmune programs, and flexibility to deploy $500M cash, including up to $150M for share buybacks, with year-end 2026 cash expected around €2B.
Gilead (Nasdaq:GILD) reported Phase 3 IDEAL trial results showing Livdelzi (seladelpar) achieved statistically significant composite ALP normalization versus placebo at 52 weeks in adults with primary biliary cholangitis (PBC) and ALP 1–1.67×ULN on or intolerant to UDCA.
The 96‑patient study showed a generally consistent safety profile with prior Livdelzi trials and no new safety concerns. Gilead plans to present full data at a medical congress and discuss results with global regulators.
Gilead (Nasdaq:GILD) reported interim Phase 3 ASSURE data for Livdelzi (seladelpar) in primary biliary cholangitis (PBC) with baseline ALP 1–1.67×ULN.
Among 50 participants, 83% achieved composite ALP normalization at 12 months and 74% at 24 months. An exploratory analysis showed 85% of biochemical responders maintained or improved liver stiffness over three years. Livdelzi was generally well tolerated with no discontinuations due to adverse events and no new safety signals. Livdelzi is approved for second-line PBC treatment in multiple regions under accelerated approval based on ALP reduction, with continued approval contingent on confirmatory benefit.
Gilead Sciences (Nasdaq:GILD) received FDA accelerated approval for Hepcludex (bulevirtide-gmod) 8.5 mg, the first and only approved U.S. treatment for chronic hepatitis delta virus (HDV) in adults, with or without compensated cirrhosis.
Approval is based on HDV RNA reductions and ALT normalization in Phase 3 MYR301; improvement in clinical outcomes is not yet established. Hepcludex carries a boxed warning for severe posttreatment exacerbation of hepatitis D and B and requires close hepatic monitoring after discontinuation.
Gilead (Nasdaq:GILD) received a CHMP positive opinion recommending Trodelvy as first-line monotherapy for unresectable locally advanced or metastatic triple-negative breast cancer in adults not eligible for PD-1/PD-L1 inhibitors.
The opinion is based on Phase 3 ASCENT-03, where Trodelvy reduced risk of progression or death by 38% versus chemotherapy. A European Commission decision is expected later in 2026.
Gilead (Nasdaq:GILD)/b) and Kite will present more than 25 abstracts, including six oral talks, at the 2026 ASCO and EHA meetings, highlighting antibody-drug conjugates and CAR T-cell therapies.Key data feature Trodelvy® in first-line metastatic TNBC, anito-cel in multiple myeloma, and KITE-753 in B‑cell lymphoma.
Gilead Sciences (Nasdaq:GILD) completed its acquisition of Germany-based biotech Tubulis, adding next-generation antibody-drug conjugate (ADC) assets and platforms to its oncology portfolio.
The deal includes $3.15 billion upfront plus up to $1.85 billion in milestones and brings lead ADCs TUB-040 and TUB-030 into Gilead’s pipeline.
Gilead Sciences (Nasdaq:GILD) renewed a five-year collaboration with the World Health Organization to help eliminate visceral leishmaniasis (VL), a fatal parasitic disease with 50,000–90,000 new cases annually. Gilead will donate over 400,000 vials of AmBisome and provide $9.2 million in support through 2030, focusing on high-burden countries, especially in East Africa.
The partnership covers countries representing about 74% of the global VL burden and builds on efforts that have reduced VL cases in Southeast Asia by more than 95% since 2005, including WHO’s 2023 validation of VL elimination as a public health problem in Bangladesh.
Gilead (Nasdaq:GILD) priced a registered public offering of $3 billion senior unsecured notes. The deal includes $500 million of 4.250% notes due 2028, $1 billion of 4.400% notes due 2029, $1 billion of 4.600% notes due 2031, and $500 million of 4.900% notes due 2034.
The offering is expected to close on May 20, 2026, subject to customary conditions. Gilead plans to use net proceeds for general corporate purposes, potentially including acquisitions, investments, strategic transactions, or other business opportunities.